| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Seshaman. Is clozapine cost-effective? Unanswered issues. The European journal of health economics : HEPAC : health economics in prevention and care. vol 3 Suppl 2. 2005-04-04. PMID:15609156. |
this review examines six key cost-effectiveness studies that address the economic considerations and quality-of-life issues associated with the use of clozapine in battling the burdens of schizophrenia to determine whether in fact the use of clozapine is clinically and economically appropriate. |
2005-04-04 |
2023-08-12 |
Not clear |
| K H Kho, B A Blansjaar, S de Vries, D Babuskova, A H Zwinderman, D H Linsze. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study. European archives of psychiatry and clinical neuroscience. vol 254. issue 6. 2005-03-29. PMID:15538604. |
electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study. |
2005-03-29 |
2023-08-12 |
Not clear |
| K H Kho, B A Blansjaar, S de Vries, D Babuskova, A H Zwinderman, D H Linsze. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study. European archives of psychiatry and clinical neuroscience. vol 254. issue 6. 2005-03-29. PMID:15538604. |
this open label study describes the efficacy of electroconvulsive therapy (ect) as adjunctive treatment in clozapine nonresponders suffering from schizophrenia. |
2005-03-29 |
2023-08-12 |
Not clear |
| Nitsan Kozlovsky, Carmit Nadri, Galila Aga. Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 15. issue 1. 2005-03-29. PMID:15572268. |
chronic treatment of rats with lithium, valproate, haloperidol or clozapine did not change rat cortical gsk-3beta protein levels ex vivo, supporting the concept that low gsk-3beta in schizophrenia is not secondary to stress or drug treatment. |
2005-03-29 |
2023-08-12 |
rat |
| Chih-Ya Cheng, Chen-Jee Hong, Shih-Jen Tsa. Effects of subchronic clozapine administration on serum glucose, cholesterol and triglyceride levels, and body weight in male BALB/c mice. Life sciences. vol 76. issue 19. 2005-03-28. PMID:15733941. |
atypical antipsychotics, like clozapine, have fewer extrapyramidal side effects compared with typical antipsychotics, however, such treatment is associated with several adverse metabolic effects such as weight gain, hyperglycemia and hyperlipidemia in patients with schizophrenia. |
2005-03-28 |
2023-08-12 |
mouse |
| Tomiki Sumiyoshi, A Roy, C-H Kim, K Jayathilake, M A Lee, C Sumiyoshi, H Y Meltze. Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. Psychopharmacology. vol 177. issue 1-2. 2005-03-23. PMID:15179543. |
clozapine has been found to improve some domains of cognition, including verbal memory, in patients with schizophrenia. |
2005-03-23 |
2023-08-12 |
Not clear |
| P M Llorca, J J Per. [Leponex, 10 years after -- a clinical review]. L'Encephale. vol 30. issue 5. 2005-03-22. PMID:15627052. |
clozapine was one of the major advances in the treatment of schizophrenia since the introduction of the classic antipsychotic agent chlorpromazine in the 1950s. |
2005-03-22 |
2023-08-12 |
Not clear |
| P M Llorca, J J Per. [Leponex, 10 years after -- a clinical review]. L'Encephale. vol 30. issue 5. 2005-03-22. PMID:15627052. |
this provides the opportunity to update the data on clozapine in the treatment of schizophrenia. |
2005-03-22 |
2023-08-12 |
Not clear |
| P M Llorca, J J Per. [Leponex, 10 years after -- a clinical review]. L'Encephale. vol 30. issue 5. 2005-03-22. PMID:15627052. |
in this article we review current clinical evidence in schizophrenia to address the following issues: 1) efficacy in refractory/positive symptoms: a systematic and critical analysis of 14 double-blind clinical trials in comparison with both standard and novel antipsychotics show consistent findings in favour of clozapine, with all but three of the reports demonstrating superiority. |
2005-03-22 |
2023-08-12 |
Not clear |
| P M Llorca, J J Per. [Leponex, 10 years after -- a clinical review]. L'Encephale. vol 30. issue 5. 2005-03-22. PMID:15627052. |
finally, the place of clozapine in the current treatment of schizophrenia is highlighted to inform the development of guidelines for clinical management. |
2005-03-22 |
2023-08-12 |
Not clear |
| R Alexander Bantick, Andrew J Montgomery, Christopher J Bench, Tariq Choudhry, Nina Malek, Peter J McKenna, Digby J Quested, J F William Deakin, Paul M Grasb. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. Journal of psychopharmacology (Oxford, England). vol 18. issue 3. 2005-03-17. PMID:15358978. |
a positron emission tomography study of the 5-ht1a receptor in schizophrenia and during clozapine treatment. |
2005-03-17 |
2023-08-12 |
human |
| R Alexander Bantick, Andrew J Montgomery, Christopher J Bench, Tariq Choudhry, Nina Malek, Peter J McKenna, Digby J Quested, J F William Deakin, Paul M Grasb. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. Journal of psychopharmacology (Oxford, England). vol 18. issue 3. 2005-03-17. PMID:15358978. |
we recruited healthy controls, and patients with schizophrenia who were divided into those receiving clozapine and those receiving neuroleptics lacking 5-ht1a receptor affinity. |
2005-03-17 |
2023-08-12 |
human |
| Robert R Conley, Deanna L Kelly, Lori L Beason-Held, Henry H Holcomb, Charles M Richardso. The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. Journal of psychopharmacology (Oxford, England). vol 18. issue 3. 2005-03-17. PMID:15358989. |
the effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. |
2005-03-17 |
2023-08-12 |
Not clear |
| Robert R Conley, Deanna L Kelly, Lori L Beason-Held, Henry H Holcomb, Charles M Richardso. The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. Journal of psychopharmacology (Oxford, England). vol 18. issue 3. 2005-03-17. PMID:15358989. |
these findings suggest that high doses of olanzapine do not produce similar brain activation patterns as clozapine in people with treatment-resistant schizophrenia. |
2005-03-17 |
2023-08-12 |
Not clear |
| Del D Miller, Vicki L Ellingrod, Timothy L Holman, Peter F Buckley, Stephan Arnd. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 133B. issue 1. 2005-03-14. PMID:15635667. |
this study included 41 patients with treatment-refractory schizophrenia (dsm-iv) who were followed prospectively during treatment with clozapine. |
2005-03-14 |
2023-08-12 |
human |
| Frank M Theisen, Anke Hinney, Torsten Brömel, Monika Heinzel-Gutenbrunner, Matthias Martin, Jürgen-Christian Krieg, Helmut Remschmidt, Johannes Hebebran. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatric genetics. vol 14. issue 3. 2005-03-07. PMID:15318026. |
we investigated the -759c/t polymorphism of the 5-ht2cr in relation to clozapine-induced change in body mass index (bmi) (kg/m) in 97 german patients with schizophrenia and found no association between the -759c allele and weight gain after 12 weeks of clozapine treatment. |
2005-03-07 |
2023-08-12 |
Not clear |
| Lynne E Rueter, Michael E Ballard, Kelly B Gallagher, Ana Maria Basso, Peter Curzon, Kathy L Kohlhaa. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology. vol 176. issue 3-4. 2005-03-01. PMID:15179541. |
chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. |
2005-03-01 |
2023-08-12 |
rat |
| Harvey Kranzler, David Roofeh, Ginny Gerbino-Rosen, Carolyn Dombrowski, Marjorie McMeniman, Courtney DeThomas, Anne Frederickson, Laurie Nusser, Mark D Bienstock, Gene S Fisch, Sanjiv Kumr. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry. vol 44. issue 1. 2005-03-01. PMID:15608544. |
clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. |
2005-03-01 |
2023-08-12 |
Not clear |
| Harvey Kranzler, David Roofeh, Ginny Gerbino-Rosen, Carolyn Dombrowski, Marjorie McMeniman, Courtney DeThomas, Anne Frederickson, Laurie Nusser, Mark D Bienstock, Gene S Fisch, Sanjiv Kumr. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry. vol 44. issue 1. 2005-03-01. PMID:15608544. |
to evaluate the effectiveness of clozapine on aggressive behavior for treatment-refractory adolescents (age range 8.5-18) with schizophrenia (295.x) at bronx children's psychiatric center. |
2005-03-01 |
2023-08-12 |
Not clear |
| P F Buckley, O Kausch, G Gardne. Clozapine treatment of schizophrenia: implications for forensic psychiatry. Journal of clinical forensic medicine. vol 2. issue 1. 2005-02-28. PMID:15335661. |
clozapine treatment of schizophrenia: implications for forensic psychiatry. |
2005-02-28 |
2023-08-12 |
Not clear |